Three physician-scientists who have relocated to Buffalo, New York, to join Roswell Park will apply highly specialized transplantation and cell therapy (TCT) expertise to both patient care and the development of New York State’s first cell therapy manufacturing and research hub: Brian Betts, MD, Kanwaldeep Mallhi, MD, and Shernan Holtan, MD.

Black patients with early-stage breast cancer who have residual disease after neoadjuvant chemotherapy were more likely to die from the disease than white patients in the same cohort, reports a multidisciplinary team of researchers from Roswell Park Comprehensive Cancer Center. Their findings, newly published in JAMA Network Open, highlight the importance of developing personalized treatment options for people of African descent who develop breast cancer.

Data from a multi-institutional research effort shed light on opportunities to improve the safety of adding immunotherapy to conventional curative therapies, underscoring the importance of close monitoring and multidisciplinary management. Led by a Roswell Park Comprehensive Cancer Center fellow, the work, newly published in The Lancet Oncology, demonstrates that the addition of immune checkpoint inhibition (ICI) to perioperative therapy was associated with increased treatment-related adverse events as well as an increasing trend of fatal toxicity.